Alzheimer's disease, ceramide, visfatin and NAD

CNS and Neurological Disorders - Drug Targets

Volumn 7, Issue 6, 2008, Pages 492-498

  Adams Jr , James D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Ceramide; NAD; Oxidative stress; Visfatin

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CERAMIDE; ENDOCANNABINOID; NEUROTROPHIN RECEPTOR P75; NICOTINAMIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TROPOMYOSIN; TROPOMYOSIN RELATED KINASE A; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; ENZYME ACTIVITY; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; LEUKOCYTE; LIPIDOSIS; MONOCYTE; NEUROPROTECTION; NEUTROPHIL; OXIDATIVE STRESS; PATHOGENESIS; PELLAGRA; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CERAMIDES; HUMANS; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 70349744498     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152708787122969     Document Type: Review

References (67)

1. Lago, F.; Dieguez, C.; Gomez-Reino, J.; Gualillo, O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev., 2007, 18, 313-25.
2. Walker. C.; Zariwala, M.; Holness, M.; Sugden, M. Diet, obesity and diabetes: a current update. Clin. Sci., 2007, 112, 93-11.
3. Ritchie, S.; Connell, J. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis., 2007, 17, 319-26.
4. Matsuzawa, Y. The metabolic syndrome and adipocytokines. FEBS Lett., 2006, 580, 2917-21.
5. Wynne, K. Free fatty acids and type 2 diabetes mellitus. Am. J. Med., 2003, 115, 29S-36S.
6. Bergman, R.; Kim, S.; Hsu, I.; Catalano, K.; Chiu, J.; Kabir, M.; Richey, J.; Ader, M. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am. J. Med., 2007, 120, S3-S8.
7. Pittas, A.; Joseph, N.; Greenberg, A. Adipocytokines and insulin resistance. J. Clin. Endocrinol. Metab., 2004, 89, 447-52.
8. Rivera, E.; Goldin, A.; Fulmer, N.; Tavares, R.; Wands, J.; de la Monte, S. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimer's Dis., 2005, 8, 247-68.
9. Arvanitakis, Z.; Schneider, J.; Wilson, R.; Li, Y.; Arnold, S.; Wang, Z.; Bennett, D. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology, 2006, 67, 1960-5.
10. Luchsinger, J.; Mayeux, R. Adiposity and Alzheimer's disease. Curr. Alzheimer Res., 2007, 4, 127-34.
11. Razay, G.; Vreugdenhil, A.; Wilcock, G. The metabolic syndrome and Alzheimer disease. Arch. Neurol., 2007, 64, 93-6.
12. Mielke, M.; Zandi, P.; Sjogren, M.; Gustafson, D.; Ostling, S.; Steen, B.; Skoog, I. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology, 2005, 64, 1689-95.
13. Siest, G.; Bertrand, P.; Qin, B.; Herbeth, B.; Serot, J.M.; Masana, L.; Ribalta, J.; Passmore, A.P.; Evans, A.; Ferrari, M.; Franceschi, M.; Shepherd, J.; Cuchel, M.; Beisiegel, U.; Zuchowsky, K.; Rukavina, A.S.; Sertic, J.; Stojanov, M.; Kostic, V.; Mitrevski, A.; Petrova, V.; Sass, C.; Merched, A.; Salonen, J.T.; Tiret, L.; Visvikis, S. Apolipoprotein E polymorphism and serum concentration in Alzheimer's Disease in nine European centres: the ApoEurope Study. Clin. Chem. Lab. Med., 2000, 38, 721-30.
14. Hall, K.; Murrell, J.; Ogunniyi, A.; Deeg M, Baiyewu O, Gao S, Gureje O, Dickens J, Evans R, Smith-Gamble V, Unverzagt FW, Shen J, Hendrie H.Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba. Neurology, 2006, 66, 223-7.
15. Glatz, J.; Luiken, J.; Bonen, A. Involvement of membrane-associated proteins in the acute regulation of cellular fatty acid uptake. J. Mol. Neurosci., 2001, 16, 123-32.
16. Costantini, C.; Weindruch, R.; Della Valle, G.; Puglielli, L. A TrkA to p75NTR molecular switch activates amyloid beta-peptide generation during aging. Biochem. J., 2005, 391, 59-67.
17. Cutler, R.; Kelly, J.; Storie, K.; Pedersen, W.; Tammara, A.; Hatanpaa, K.; Troncoso, J.; Mattson, M. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101, 2070-5.
18. Katsel, P.; Li, C.; Haroutunian, V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem. Res., 2007, 32, 845-56.
19. Satoi, H.; Tomimoto, H.; Ohtani, R.; Kitano, T.; Kondo, T.; Watanabe, M.; Oka, N.; Akiguchi, I.; Furuya, S.; Hirabayashi, Y.; Okazaki, T. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience, 2005, 130, 657-66.
20. Marks, N.; Berg, M.; Saito, M.; Saito, M. Glucosylceramide synthase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: consequences of morphology and viability on enzyme suppression in cultured primary neurons. Brain Res., 2008, 1191, 136-47.
21. Han, X.; Holtzman, D.; McKeel, D.; Kelley, J.; Morris, J. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: a potential role in disease pathogenesis. J. Neurochem., 2002, 82, 809-18.
22. Kalvodova, L.; Kahya, N.; Schwille, P.; Ehehalt, R.; Verkade, P.; Drechsel, D.; Simons, K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J. Biol. Chem., 2005, 280, 36815-23.
23. Cutler, R.; Kelly, J.; Storie, K.; Pedersen, W.; Tammara, A.; Hatanpaa, K.; Troncoso, J.; Mattson, M. Involvement of oxidative stress induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101, 2070-5.
24. Grimm, M.; Grimm, H.; Hartmann, T. Amyloid beta as a regulator of lipid homeostasis. Trends Mol. Med., 2007, 13, 337-44.
25. Li, H.; Junk, P.; Huwiler, A.; Burkhardt, C.; Wallerath, T.; Pfeilschifter, J.; Forstermann, U. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation, 2002, 106, 2250-6.
26. Chen, S.; Hu, C.; Yang, D.; Nassief, A.; Chen, H.; Yin, K.; Xu, J.; Hsu, C. Pravastatin attenuates ceramide induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation. Ann. NY Acad. Sci., 2005, 1042, 357-64.
27. Eldreich-Epstein, A.; Tran, L.; Cox, O.; Huang, E.; Laug, W.; Shimada, H.; Millard, M. Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphvbeta5 involves ceramide metabolic pathways. Blood, 2005, 105, 4353-61.
28. Stamatovic, S.; Shakui, P.; Keep, R.; Moore, B.; Kunkel, S.; Van Rooijen, N.; Andjelkovic, A. Monocyte chemoattractant protein-1 regulation of blood brain barrier permeability. J. Cereb. Blood Flow Metab., 2005, 25, 593-606.
29. Fiala, M.; Liu, Q.; Sayre, J.; Pop, V.; Brahmandam, V.; Graves, M.; Vinters, H. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur. J. Clin. Invest., 2002, 32, 360-71.
30. Schatter, B.; Jin, S.; Loffelholz, K.; Klein, J. Cross talk between phosphatidic acid and ceramide during ethanol induced apoptosis in astrocytes. BMC Pharmacol., 2005, 5, 3.
31. Jana, A.; Pahan, K. Fibrillar amyloid beta peptides kill human primary neurons via NADPH oxidase mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J. Biol. Chem., 2004, 279, 51451-9.
32. Arboleda, G.; Huang, T.; Waters, C.; Verkhratsky, A.; Fernyhough, P.; Gibson, R. Insulin like growth factor 1 dependent maintenance of neuronal metabolism through phosphatidylinositol 3-kinase Akt pathway is inhibited by C2-ceramide in CAD cells. Eur. J. Neurosci., 2007, 25, 3030-8.
33. Gong, C.; Liu, F.; Grundke-Iqbal, I.; Iqbal, K. Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. J. Alzheimer's Dis., 2006, 9, 1-12.
34. Hoyer, S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol., 2004, 490, 115-25.
35. Matia, I.; Di Marzo, V. Endocannabinoids and the control of energy balance. Trends Endocrinol. Metab., 2006, 18, 27-37.
36. Centonze, D.; Finazzi-Agro, A.; Bernardi, G.; Maccarrone, M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci., 2007, 28, 180-7.
37. Esposito, G.; Iuvone, T.; Savani, C.; Scuderi, C.; De Filippis, D.; Papa, M.; Di Marzo, V.; Steardo, L. Opposing control of cannabinoid receptor stimulation on amyloid beta induced reactive gliosis: in vitro and in vivo experiments. J. Pharmacol. Exp. Ther., 2007, 322, 1144-52.
38. Boyd, S. The endocannabinoid system. Pharmacotherapy, 2006, 26, 218S-221S.
39. Gasperi, V.; Fezza, F.; Pasqariello, N.; Bari, M.; Oddi, S.; Agro, A.; Maccarone, M. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell. Molec. Life Sci., 2007, 64, 219-29.
40. Bingham, E.; Hopkins, D.; Smith, D.; Pernet, A.; Hallett, W.; Reed, L.; Marsden, P.; Amiel, S. The role of insulin in human brain glucose metabolism: an 18fluorodeoxyglucose positron emission tomography study. Diabetes, 2002, 51, 3384-90.
41. Sethi, J.; Vidal-Puig, A. Visfatin: the missing link between intra-abdominal obesity and diabetes. Trends Molec. Med., 2005, 11, 344-7.
42. Revollo, J.; Grimm, A.; Imai, S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr. Opin. Gastroenterol., 2007, 23, 164-70.
43. Haskell, C.; Wong, M.; Williams, A.; Lee, L. Phase 1 trial of extracellular ATP in patients with advanced cancer. Med. Ped. Oncol., 1996, 27, 165-73.
44. Berger, F.; Ramirez-Hernandez, M.; Ziegler, M. The new life of a centenarian: signaling functions of NAD(P). Trends Biochem. Sci., 2004, 29, 111-8.
45. Beckman, J.; Parks, D.; Pearson, J.; Marshall, P.; Freeman, B. A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues. Free Rad. Biol. Med., 1989, 6, 607-15.
46. Ellis, E.; Guberski, D.; Hutson, B.; Grant M. Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat. Nitric Oxide Biol. Chem., 2002, 6, 295-304.
47. Martin-Romero, F.; Garcia-Martin, E.; Gutierrez-Merino, C. Inhibition of oxidative stress produced by plasma membrane NADH oxidase delays low potassium induced apoptosis of cerebellar granule cells. J. Neurochem., 2002, 82, 705-15.
48. Peng, T.; Lu, X.; Feng, Q. Pivotal role of gp91phox containing NADH oxidase in lipopolysaccharide induced tumor necrosis factor alpha expression and myocardial depression. Circulation, 2005, 111, 1637-44.
49. Malik, S.; Vaillant, F.; Lawen, A. Plasma membrane NADH oxidoreductase in cells carrying mitochondrial DNA G11778A mutation and in cells devoid of mitochondrial DNA (rhoO). Biofactors, 2004, 20, 189-98.
50. Lupke, M.; Rollwitz, J.; Simko, M. Cell activating capacity of 50 Hz magnetic fields to release reactive oxygen intermediates in human umbilical cord blood derived monocytes and in mono Mac 6 cells. Free Rad. Res., 2004, 38, 985-93.
51. Morre, D.; Guo, F.; Morre, D. An aging related cell surface NADH oxidase (arNOX) generates superoxide and is inhibited by coenzyme Q. Mol. Cell. Biochem., 2003, 254, 101-9.
52. Berridge, M.; Tan, A. Cell surface NAD(P)H oxidase: relationship to trans plasma membrane NADH oxidoreductase and a potential source of circulating NADH oxidase. Antioxide Redox Signal., 2000, 2, 277-88.
53. Sumimoto, H.; Miyano, K.; Takeya, R. Molecular composition and regulation of the Nox family NAD(P)H oxidases. Biochem. Biophys. Res. Commun., 2005, 338, 677-86.
54. Markert, C.; Morre, D.; Morre, D. Human amyloid peptides Abeta1-40 and Abeta1-42 exhibit NADH oxidase activity with copper induced oscillations and a period length of 24 min. Biofactors, 2004, 20, 207-21.
55. Adams, J.; Klaidman, L. Sirtuins, nicotinamide and aging: a critical review. Lett. Drug Des. Disc., 2007, 4, 44-8.
56. Belenky, P.; Bogan, K.; Brenner, C. NAD metabolism in health and disease. Trends Biochem. Sci., 2006, 32, 12-19.
57. Snell, C.; Snell, P.; Richards, C. Degradation of NAD by synaptosomes and its inhibition by nicotinamide mononucleotide: implications for the role of NAD as a synaptic modulator. J. Neurochem., 1984, 43, 1610-5.
58. Lauhon, C.; Szostak, J. RNA aptamers that bind flavin and nicotinamide redox cofactors. J. Am. Chem. Soc., 1995, 117, 1246-57.
59. Dahl, T.; Yndestad, A.; Skjelland, M.; Oje, E.; Dahl, A.; Michelsen, A.; Damas, J.; Tunheim, S.; Ueland, T.; Smith, C.; Bendz, B.; Tonstad, S.; Gullestad, L.; Froland, S.; Krohg-Sorensen, K.; Russell, D.; Aukrust, P.; Halvorsen, B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation, 2007, 115, 972-80.
60. Moschen, A.; Kaser, A.; Enrich, B.; Mosheimer, B.; Theurl, M.; Niederegger, H.; Tilg, H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol., 2007, 178, 1748-58.
61. Altura, B.; Gebrewold, A.; Tao, Z.; Altura, B. Sphingomyelinase and ceramide analogs induce vasoconstriction and leukocyte-endothelial interactions in cerebral venules in the intact rat brain: Insight into mechanisms and possible relation to brain injury and stroke. Brain Res. Bull., 2002, 58, 271-8.
62. Rex, A.; Spychalla, M.; Fink, H. Treatment with reduced nicotinamide adenine dinucleotide (NADH) improves water maze performance in old Wistar rats. Behav. Brain Res., 2004, 154, 149-53.
63. Demarin, V.; Podobnik, S.; Storga-Tomic, D.; Kay, G. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double blind study. Drugs Under Exp. Clin. Res., 2004, 30, 27-33.
64. Birkmayer, J. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann. Clin. Lab. Sci., 1996, 26, 1-9.
65. Rainer, M.; Kraxberger, E.; Haushofer, M.; Mucke, H.; Jellinger, K. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. J. Neural Transm., 2000, 107, 1475-81.
66. Yang, J.; Adams, J. Current developments in nicotinamide pharmacology. Curr. Topics Pharmacol., 2002, 6, 171-83.
67. Klaidman, L.; Mukherjee, S.; Adams, J. Oxidative changes in brain pyridine nucleotides and neuroprotection using nicotinamide. Biochim. Biophys. Acta, 2001, 1525, 136-148.